Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026

(NASDAQ: VKTX) Viking Therapeutics, Inc. announced it will present two posters highlighting its VK2735 program at The Obesity Society's Annual Meeting, ObesityWeek®, taking place from November 14–17, 2026. VK2735 is described as a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, being developed in both subcutaneous and oral formulations for the potential treatment of various metabolic disorders, including obesity. The first poster, titled 'VANQUISH-2 SC VK2735 Study in Adults With Overweight and Type 2 Diabetes: Baseline Characteristics,' will be presented by Jamy Ard, MD, FTOS, on Saturday, November 14, 2026, from 7:30 pm to 8:30 pm ET during Poster Session 1 in Exhibit Hall BCD, Gaylord National Resort & Convention Center. The second poster, titled 'Impact of SC VK2735 on Obesity Severity and Cardiometabolic Parameters in the VENTURE Study,' will be presented by Harold Bays, MD, MFOMA, FTOS, FACC, FNLA, FASPC, DABOM, on Sunday, November 15, 2026, from 2:30 pm to 3:30 pm ET during Poster Session 2 at the same location. Viking Therapeutics states that VK2735 is currently being evaluated in Phase 3 clinical studies for obesity, with maintenance dosing strategies designed to support long-term weight management. The company is also advancing additional obesity programs, including VK3019, an amylin receptor agonist, and VK2809, an orally available thyroid hormone receptor beta agonist for metabolic and liver disease. VK0214 is being developed for the rare genetic disorder X-linked adrenoleukodystrophy (X-ALD). The company describes itself as a clinical-stage biopharmaceutical company advancing a next-generation portfolio of therapies for obesity and metabolic disease. Viking Therapeutics emphasizes its focus on innovative treatments to help people achieve meaningful, lasting health improvements by treating obesity first. The company highlights its deep expertise in metabolic biology and rigorous science as guiding principles for its development programs. The announcement includes the company's website for further information. The release also contains forward-looking statements regarding Viking's expectations for its clinical and preclinical development programs, anticipated timing for reporting clinical data, and cash resources.

Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

(NASDAQ:VKTX) Viking Therapeutics, Inc. announced its financial results for the third quarter and nine months ended September 30, 2026, and provided an update on its clinical pipeline and corporate developments. The company reported a strong quarter-end cash position of $960 million, following concurrent upsized public offerings of common stock and convertible senior notes. Viking continued to advance its obesity franchise, with the VANQUISH Phase 3 trials for subcutaneous VK2735 in obesity (VANQUISH-1 and VANQUISH-2) ongoing. VANQUISH-1 enrolled approximately 4,500 patients within five months, and VANQUISH-2 enrolled approximately 1,000 patients within nine months. Both trials are randomized, double-blind, placebo-controlled, multicenter studies assessing VK2735 administered by subcutaneous injection once weekly for 78 weeks, with primary endpoint being percent change in body weight from baseline compared to placebo. Participants are randomized to weekly doses of 7.5 mg, 12.5 mg, 17.5 mg, or placebo. Secondary and exploratory endpoints include the percentage of patients achieving at least 5%, 10%, 15%, and 20% weight loss. Extension studies for VANQUISH will commence in the first quarter of 2027, allowing participants to continue treatment for up to an additional 52 weeks, with results anticipated in 2028. The SUNRISE Phase 3 program for oral VK2735 has been initiated, with SUNRISE-1 and SUNRISE-2 trials each targeting enrollment of 560 adults, randomized to once-daily doses of 27.5 mg, 35 mg, 55 mg, or placebo for 68 weeks. Top-line data from the prior Phase 2 VENTURE study of VK2735 in adults with obesity showed statistically significant reductions in mean body weight from baseline, up to 14.7% after 13 weekly doses for the subcutaneous formulation, and up to 12.2% after 13 weeks for the oral formulation. In the oral study, up to 80% of VK2735-treated subjects achieved at least 10% weight loss after 13 weeks, compared to 5% for placebo. The company announced positive results from Part 1 of a VK2735 maintenance dosing study, where week 21 weight loss ranged from approximately 16% to 19% for VK2735, compared to approximately 0% for placebo. Among VK2735-treated subjects, 98% achieved 5% weight loss, 90% achieved 10%, 65% achieved 15%, and 32% achieved 20% weight loss, versus 13% for 5% weight loss and 0% for higher thresholds in placebo. After transitioning to every-other-week or monthly dosing, mean weight loss retained at week 33 ranged from 83% to 97% (every-other-week) and 82% to 90% (monthly), compared to 61% for placebo. Participants maintained on a 17.5 mg weekly dose for 33 weeks reached approximately 22% weight loss from baseline. The maintenance study demonstrated a favorable tolerability profile, with GI-related adverse events low and similar to placebo. Part 2 of the maintenance dosing study has been initiated to evaluate additional oral and subcutaneous regimens. The Phase 1 study of VK3019, a dual amylin and calcitonin receptor agonist, is nearing completion, with a 28-day multiple ascending dose study planned for the first quarter of 2027.

Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity

(NASDAQ:VKTX) Viking Therapeutics, Inc. announced the initiation of the SUNRISE Phase 3 clinical program for oral VK2735, a dual agonist of the GLP-1 and GIP receptors, for the treatment of obesity and type 2 diabetes. The SUNRISE program consists of two randomized, double-blind, placebo-controlled, multicenter trials: SUNRISE-1, enrolling obese or overweight adults without type 2 diabetes but with at least one weight-related comorbidity, and SUNRISE-2, enrolling obese or overweight adults with type 2 diabetes. Each study will enroll 560 adults, with participants randomized to receive once-daily oral VK2735 at doses of 27.5 mg, 35 mg, 55 mg, or placebo for 68 weeks. The primary endpoint for both trials is the percent change in body weight from baseline after 68 weeks, with secondary and exploratory endpoints including the percentage of patients achieving at least 5%, 10%, 15%, or 20% body weight reduction. Brian Lian, Ph.D., chief executive officer of Viking, stated that advancing oral VK2735 into Phase 3 is an important step for the company's obesity portfolio and highlighted the potential for oral VK2735 to be used as induction or maintenance therapy. In 2025, Viking reported positive top-line results from the Phase 2 VENTURE-Oral Dosing study, where patients receiving once-daily oral VK2735 achieved up to 12.2% mean body weight reduction from baseline after 13 weeks, with statistically significant differences versus placebo for all doses greater than 15 mg starting at Week 1. Up to 97% of patients on VK2735 achieved at least 5% weight loss, and up to 80% achieved at least 10% weight loss, compared to 10% and 5% of placebo patients, respectively. Safety data from Phase 2 showed that 98% of drug-related treatment-emergent adverse events were mild or moderate, with gastrointestinal events being the most common and generally subsiding with continued dosing. Progressive dose escalation in 30 mg increments allowed rapid advancement to higher doses while maintaining tolerability. Viking is also conducting a maintenance dosing trial of oral VK2735 and two Phase 3 studies (VANQUISH-1 and VANQUISH-2) evaluating subcutaneous VK2735. VANQUISH-1 is fully enrolled with approximately 4,500 adults without type 2 diabetes who are obese or overweight with at least one weight-related comorbidity, and VANQUISH-2 is fully enrolled with approximately 1,000 adults with type 2 diabetes who are obese or overweight. Both VANQUISH trials randomize patients to weekly subcutaneous VK2735 doses of 7.5 mg, 12.5 mg, 17.5 mg, or placebo for 78 weeks. A correction note clarified that the oral VK2735 maintenance dosing trial evaluates daily oral, monthly subcutaneous, every-other-week subcutaneous, or placebo dosing, not weekly oral doses as previously stated. Viking is also advancing additional obesity and metabolic disease programs, including VK3019, VK2809, and VK0214.

Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026

(NASDAQ: VKTX) Viking Therapeutics, Inc. announced that the company will release financial results for the second quarter of 2026 after the market close on Wednesday, July 29, 2026. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, July 29, 2026. A telephone replay will be accessible until August 5, 2026, by dialing (855) 669-9658 from the U.S. and Canada, or (412) 317-0088 and entering conference ID # 7609005. An archive of the webcast will also be available on the Webcasts page of the company's website for 30 days. Viking Therapeutics, Inc.'s lead program, VK2735, is a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist in development in both subcutaneous and oral formulations for obesity. VK2735 is currently being evaluated in Phase 3 clinical studies for obesity, and a Phase 1 study designed to evaluate maintenance dosing strategies to support long-term weight management. Viking's pipeline also includes VK3019, VK2809, and VK0214 for various metabolic and rare genetic disorders.

Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm

(NASDAQ: VKTX) Kuehn Law, PLLC announced it is investigating whether certain officers and directors of Viking Therapeutics, Inc. breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms. The consultation and case are free with no obligation to you. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights. For additional information, please visit Shareholder Derivative Litigation - Kuehn Law.

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

(NASDAQ: VKTX) Viking Therapeutics, Inc. announced the initiation of a Phase 1 single ascending dose (SAD) clinical trial of VK3019, an investigational dual amylin and calcitonin receptor agonist (DACRA) being developed as a potential treatment option for weight loss. The Phase 1 trial is a randomized, double-blind, placebo-controlled SAD study in healthy adults with BMI ≥30, with primary objectives including evaluating the safety, tolerability, and pharmacokinetics of single subcutaneous doses of VK3019. Preclinical data from Viking's internally developed DACRAs showed reduced food intake in lean rats within 0 to 72 hours after a single dose and up to 8% reduction in body weight at 72 hours compared to controls. Viking is also conducting the Phase 3 VANQUISH studies of subcutaneous VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, in patients with obesity or who are overweight, with each study administering VK2735 by subcutaneous injection once weekly for 78 weeks. The company is advancing both subcutaneous and oral tablet formulations of VK2735, with plans to initiate a Phase 3 trial to evaluate oral VK2735 for the treatment of obesity and overweight later this year. In October 2025, Viking initiated a Phase 1 study to explore various VK2735 maintenance dosing regimens, and expects to report the results of the study in 3Q26. Data from a Phase 1 and a Phase 2 trial evaluating subcutaneous VK2735 demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit.

Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer

(NASDAQ:VKTX) Viking Therapeutics, Inc. announced the appointment of Hubert C. Chen, M.D., as chief medical officer. Dr. Chen brings more than two decades of leadership experience in senior executive roles spanning drug discovery, clinical development, regulatory strategy, and product approvals across multiple therapeutic areas. Viking is evaluating its subcutaneous formulation of VK2735 in a Phase 3 obesity program that includes two Phase 3 clinical trials (VANQUISH-1 and VANQUISH-2). Data from a Phase 1 and a Phase 2 trial evaluating subcutaneous VK2735 demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. The company is also evaluating an oral formulation of VK2735 in a Phase 2 trial in obesity. VK2809, another compound, successfully achieved both the primary and secondary endpoints in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. The company projects further development of its clinical and preclinical programs, anticipated timing for reporting clinical data, and cash resources.

Viking Therapeutics to Participate at Upcoming Investor Conferences

Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company, announced its participation in two upcoming conferences: the William Blair 46th Annual Growth Stock Conference and the Jefferies Global Healthcare Conference in June. Viking management will deliver a corporate presentation, participate in breakout sessions, and hold investor meetings at these events. The company is advancing several clinical programs, including VK2735 for obesity and metabolic disorders, VK2809 for lipid and metabolic disorders, and VK0214 for X-linked adrenoleukodystrophy (X-ALD). VK2735 is being evaluated in a Phase 3 obesity program and has shown an encouraging safety and tolerability profile with positive signs of clinical benefit in earlier trials. VK2809 achieved both primary and secondary endpoints in a Phase 2b study for NASH and fibrosis, and demonstrated statistically significant reductions in LDL-C and liver fat content in a Phase 2a trial. VK0214 was shown to be safe and well-tolerated in a Phase 1b trial, with significant reductions in plasma VLCFAs and other lipids. Investors can access a live webcast of the Jefferies fireside chat and a replay on the Viking website. The announcement highlights the company's ongoing clinical development and upcoming investor engagement.

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Viking Therapeutics, Inc. (NASDAQ: VKTX) announced it will present two posters on its VK2735 program at the 33rd European Congress on Obesity (ECO) in Istanbul, Türkiye, on May 12-15, 2026. The presentations will highlight data from the 13-week Phase 2 VENTURE-Oral trial and participant characteristics from the ongoing Phase 3 VANQUISH-1 trial of subcutaneous VK2735. VK2735 is a dual agonist of the GLP-1 and GIP receptors being developed for metabolic disorders, including obesity. The company is also developing other compounds such as VK2809 and VK0214 for metabolic and rare diseases. These developments are significant for investors as they demonstrate progress in Viking's clinical pipeline and ongoing research activities.

Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026

Viking Therapeutics, Inc. announced that it has scheduled a conference call for Wednesday, April 29 at 4:30 p.m. Eastern Time. The announcement was made from SAN DIEGO on April 22, 2026. Viking Therapeutics is described as a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine conditions. The company is listed on NASDAQ under the ticker VKTX. This announcement is relevant to investors as it provides information on an upcoming event where the company may discuss recent developments or financial results.